High prevalence of XXXX in long-term survivors after allogeneic bone marrow transplantation for @entity1503 .

@entity1 @entity1375 @entity11157 @entity9646 @entity10972 @entity442 @entity1378 @entity1503 @entity177 @entity2132 @entity3214 @entity4903 @entity1374
BACKGROUND: The progressively increasing number of long-term survivors after allogeneic bone marrow transplantation (allo-BMT) led researchers to focus on the early and late complications of this procedure. Endocrine dysfunction occurred mostly in @entity1 who had undergone total body irradiation (TBI) as part of pretransplantation treatment. The extent to which chemotherapy and immune system derangement affect endocrine function in allo-BMT recipients is still unclear. METHODS: Forty consecutive @entity1 (21 @entity1 , 19 @entity1 ) with @entity1503 surviving 12 or more months after allo-BMT from HLA-identical siblings were studied. @entity1 ' age at transplantation ranged from 13 to 45 years and their post-BMT follow-up lasted 12-62 months. The conditioning regimen BUCY2 was employed. @entity2132 ( @entity2132 ) was observed in the acute form in 13 @entity1 and in the chronic form in 26. The function of hypothalamic-pituitary-gonad, thyroid, somatotrophic, and adrenal axes was assessed. RESULTS: The most common @entity4903 was @entity11157 (95% of @entity1 ), followed by an increase in follicle-stimulating hormone in 47% of @entity1 , indicating spermatogenesis damage. @entity9646 replacement therapy was contraindicated in three @entity1 because of chronic liver @entity2132 and it was ineffective partially in four others because of reduced intestinal or cutaneous absorption. @entity1374 occurred in 47.5% of @entity1 and included @entity3214 , @entity10972 , and transient @entity1378 and @entity1375 . Adrenal function was abnormal in 10%, mostly related to the prolonged corticosteroid treatment. @entity442 was lower than age-reference values in 27% of all @entity1 and in 38% of those with chronic @entity2132 . Thyroid, adrenal, and @entity442 impairments were more frequent in @entity1 with chronic @entity2132 than in @entity1 without this disease (P = 0.048). CONCLUSIONS: A high prevalence of @entity4903 was detected in a cohort of allo-BMT recipients not treated by TBI. Although @entity177 was likely related to intensive myeloablative treatments, thyroid, adrenal, and @entity442 impairments were late events, suggesting that immunosuppressive treatment and immune system derangement may play a role in the development of @entity4903 after allografting.
